Introduction#
Editas Medicine, a biotechnology company based in Cambridge, Massachusetts, has announced that it will present five research abstracts at various scientific conferences in May. This comes amid recent fluctuations in its stock price, which has dropped 18% over the past week despite a strong 42% gain year-to-date.
Upcoming Presentations#
The company will participate in the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting from May 11-15, where it will deliver one oral presentation and two poster presentations. Additionally, Editas will present at the TIDES USA 2026 Conference and the 94th European Atherosclerosis Society (EAS) Congress later in May.
Focus on EDIT-401#
One of the key presentations will focus on EDIT-401, a gene therapy designed to help lower cholesterol levels in individuals with high cholesterol, known as hyperlipidemia. The oral presentation, titled "Preclinical Development of EDIT-401, a Durable In Vivo CRISPR Gene Editing Therapy That Upregulates LDLR Protein to Lower LDL-C," is scheduled for May 14 at 3:30 p.m. EDT. The poster presentations will cover important data related to how the therapy works in animal models.
Recent Developments#
In addition to its upcoming presentations, Editas Medicine has made changes to its accounting firm, switching from Ernst & Young to PricewaterhouseCoopers for the fiscal year ending December 31, 2026. The company is also involved in a patent dispute regarding CRISPR technology, with the U.S. Patent and Trademark Office recently reaffirming a decision in favor of the Broad Institute. Analysts have responded positively to Editas's progress, with upgrades in stock ratings from various firms, reflecting confidence in the company's gene therapy advancements and financial stability.